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Abstract
Prostate cancer exhibits tremendous variability in clinical behavior, ranging from indolent to lethal disease. Better
prognostic markers are needed to stratify patients for appropriately aggressive therapy. By expression profiling, we can
identify a proliferation signature variably expressed in prostate cancers. Here, we asked whether one or more tissue
biomarkers might capture that information, and provide prognostic utility. We assayed three proliferation signature genes:
MKI67 (Ki-67; also a classic proliferation biomarker), TOP2A (DNA topoisomerase II, alpha), and E2F1 (E2F transcription factor
1). Immunohistochemical staining was evaluable on 139 radical prostatectomy cases (in tissue microarray format), with a
median clinical follow-up of eight years. Each of the three proliferation markers was by itself prognostic. Notably, combining
the three markers together as a ‘‘proliferation index’’ (0 or 1, vs. 2 or 3 positive markers) provided superior prognostic
performance (hazard ratio=2.6 (95% CI: 1.4–4.9); P=0.001). In a multivariate analysis that included preoperative serum
prostate specific antigen (PSA) levels, Gleason grade and pathologic tumor stage, the composite proliferation index
remained a significant predictor (P=0.005). Analysis of receiver-operating characteristic (ROC) curves confirmed the
improved prognostication afforded by incorporating the proliferation index (compared to the clinicopathologic data alone).
Our findings highlight the potential value of a multi-gene signature-based diagnostic, and define a tri-marker proliferation
index with possible utility for improved prognostication and treatment stratification in prostate cancer.
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Introduction
Prostate cancer is a leading cause of cancer death in the United
States [1]. Despite that, prostate cancer exhibits considerable
variability in clinical behavior. Many (if not most) prostate cancers
are clinically indolent, while others are clinically aggressive,
becoming metastatic and lethal. For localized prostate cancer,
treatment options range from active surveillance (‘‘watchful
waiting’’) to decisive surgical excision (radical prostatectomy) or
radiation therapy [2,3]. Docetaxel chemotherapy is also being
evaluated in the adjuvant and neoadjuvant setting [4]. Increas-
ingly, there is a need for prognostic biomarkers to accurately
stratify patients for appropriate risk-adapted therapy.
Current prognostic factors include Gleason grade, tumor stage,
and preoperative serum PSA [5–8], and nomograms that combine
such data [9,10]. However, much uncertainty remains, and as
such many men opt for unnecessarily aggressive therapy. Other
measures, e.g. tumor histology, DNA ploidy, proliferation
markers, and selected cancer genes, are also under evaluation
[11–15]. Of these, markers of tumor cell proliferation, e.g. S-phase
fraction or Ki-67 immunostaining, are already in clinical use for
other cancer types, including for example breast cancer [16],
gastroentero-pancreatic neuroendocrine tumors [17], and mantle
cell lymphoma [18].
In prior studies, we used DNA microarrays to profile gene
expression in prostate cancer [19]. Unsupervised clustering of
expression profiles revealed distinct tumor clusters (defining
molecular subtypes), as well as distinct clusters (or ‘‘features’’) of
co-expressed genes, identifying the underlying biological pathways
and processes. Among these, one prominent gene-expression
feature ostensibly reflected tumor cell proliferation levels, and its
expression varied substantially across prostate cancers. Here, we
set out to characterize proliferation-signature genes as tissue
biomarkers, and to evaluate their prognostic utility.
Methods
Molecular signatures
To evaluate a cell proliferation signature in prostate cancer, we
analyzed previously published [19] cDNA microarray gene-
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These  authors  are  joint  senior  authors  on  this  work.expression profiles from 71 prostate cancer and 41 normal prostate
(uninvolved tissue from the opposite lobe) specimens. The
microarray data are MIAME compliant, and the raw data are
accessible at GEO (accession GSE3933). Hierarchical clustering
[20] was applied to the 7,957 genes (cDNAs) that were both well
measured (signal/background .1.5 in at least 50% of specimens)
and variably expressed ($2-fold expression change from the
median in at least 2 specimens). A gene cluster that included many
genes with known roles in cell proliferation (a putative ‘‘prolifer-
ation signature’’ cluster) was further evaluated. Overlaps between
the putative proliferation-signature cluster (containing 94 unique
genes) and 639 canonical pathway (BioCarta and KEGG) gene
sets were evaluated using the Molecular Signatures Database
(MSigDB) [21] ‘‘compute overlap’’ function, based on the
hypergeometric distribution. Ki-67, TOP2A and E2F1 were
selected from among the proliferation signature genes based on
the availability of antibodies suitable for immunohistochemistry on
formalin-fixed, paraffin-embedded tissue.
Tissue microarray cohort
A tissue microarray included 139 fully evaluable formalin-
fixed, paraffin-embedded primary prostate tumors selected from
diagnostic radical prostatectomy cases performed at Stanford
University Hospital between 1986 and 1996, with Institutional
Review Board approval and written patient consent (protocol ID
11612) [19]. Each case was represented by duplicate 0.6 mm
Table 1. Clinicopathological characteristics of tissue
microarray cases.
Clinicopathologic feature Number of cases (%)
Preoperative PSA (ng/ml)
0–10 83 (60%)
10–20 44 (32%)
$20 12 (9%)
Gleason grade
a
3+3 20 (14%)
3+4 95 (68%)
4+3 22 (16%)
$4+4 2 (1%)
Pathologic stage
T2 13 (9%)
T2b 65 (47%)
T3a 42 (30%)
T3b 11 (8%)
T4 8 (6%)
aDetermined from pathology report (not tissue microarray core).
doi:10.1371/journal.pone.0020293.t001
Figure 1. A proliferation signature cluster in prostate cancer. (A) Unsupervised cluster analysis of prostate cancers (data set from ref. [19])
reveals molecular subtypes of prostate cancer (1, 2 and 3, labeled), and gene-expression features reflecting underlying biological processes. Left,
thumbnail heatmap of the cluster analysis. Right, enlarged view of the ‘‘proliferation cluster’’, with selected genes shown (MKI67, TOP2A and E2F1 in
red text, marked by arrow). Red and green expression levels reflect high and low values, respectively (see key). Red filled circles (below) identify lymph
node metastases. (B) Overlap matrix of proliferation cluster genes (N=94) with canonical pathway (CP) gene sets identifies top gene set matches (all
significant, P,0.001) all relating to cell-cycle/proliferation. Solid blue fill indicates overlapping membership between proliferation cluster and queried
gene sets.
doi:10.1371/journal.pone.0020293.g001
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summarized in Table 1. Patients were treated by radical
prostatectomy alone, and clinical follow-up every 6 months
included PSA testing and physical examination; the median
clinical follow-up was 8 years.
Immunohistochemistry
Serial sections of 4 mm were cut from the tissue microarray
block, de-paraffinized in Citrisolv (Fisher Scientific, Pittsburgh,
PA), and hydrated in a graded series of alcohol solutions. Heat-
induced antigen retrieval was performed by microwave pretreat-
ment in citrate (1 mM, pH 6.0) for 15 minutes before staining.
Endogenous peroxidase was blocked by preincubation with 1%
hydrogen peroxide in phosphate-buffered saline. Ki-67 mouse
monoclonal antibody (MIB-1; Dako, North America, Carpinteria,
CA) was used at 1:100 dilution, TOP2A mouse monoclonal
antibody (SWT3D1; Research Diagnostics, Flanders, NJ) at 1:10
dilution, and E2F1 mouse monoclonal antibody (18E10; Gene-
Tex, Irvine, CA) at 1:200 dilution, each for 30 min. Chromogenic
detection was carried out using a peroxidase-conjugated secondary
antibody and DAB reagents provided with the Envision detection
kit (Dako). Immunostains were scored by a pathologist (J.P.H)
blinded to clinical data, and the criteria for positivity set to provide
a dynamic range. For Ki-67 and TOP2A, strong staining in $5%
tumor nuclei was scored as positive. For E2F1, which stained a
higher proportion of nuclei, strong staining in $50% tumor nuclei
was scored as positive. If either duplicate core scored positive, the
case was considered positive.
Statistical analysis
Correlations between proliferation biomarkers were assessed by
Pearson correlation. Associations between proliferation biomark-
ers and clinicopathologic variables were evaluated by Fisher’s
exact test. Kaplan-Meier plots and the log-rank test were used to
test the equality of the survivor functions across prostate cancer
groups. Multivariate Cox proportional hazards regression analysis,
with ties handled by the Efron appoximation, was used to identify
the significant predictors of PSA recurrence. Receiver-operating
characteristic (ROC) curves were evaluated for the significant
predictors of PSA recurrence. All analyses were performed using
the R statistical software package and WinStat software (R. Fitch
Software, Chicago, IL).
Results
In our prior studies, expression profiling of prostate cancers
revealed distinct molecular subgroups, as well as gene-expression
features reflecting underlying biological processes [19]. In a re-
analysis of those data, one prominent gene-expression feature
(Fig. 1A) included genes regulating the cell-cycle (e.g. CCNE1,
CDK1, CDC25A), and involved in DNA replication (e.g. POLE2,
MCM4, TK1) and chromosome dynamics (e.g. SMC4, CENPE),
ostensibly reflecting tumor cell proliferation levels. This feature
was variably expressed across prostate cancers, and particularly
prominent among lymph node metastases, and a subset of primary
tumors within molecular subtypes 2 and 3, subgroups previously
found to be more clinically-aggressive [19]. Evaluating overlaps
between this cluster of genes and canonical pathway gene sets
within the Molecular Signature Database [21] confirmed a
connection to cell proliferation; the top five significantly
(P,0.01) overlapping gene sets all related to cell-cycle/prolifera-
tion pathways (Fig. 1B).
High proliferation rates in cancers are typically associated with
worse clinical outcome. We therefore sought to evaluate the
prognostic value of proliferation signature genes, individually and
in combination, in prostate cancer. Based on the availability of
antibodies suitable for immunohistochemistry on formalin-fixed,
paraffin-embedded tissue, we chose to focus on three proliferation
signature genes, MKI67 (encoding the classic cell proliferation
marker, Ki-67) [22], TOP2A (DNA topoisomerase II, alpha), and
E2F1 (E2F transcription factor 1) (Fig. 1A).
Table 2. Association of proliferation markers with
clinicopathologic variables.
Proliferation
biomarker Clinicopathologic parameter P-value
a
Ki-67 Preoperative PSA ($10 vs. ,10 ng/ml) 0.85
Gleason grade ($4+3 vs. #3+4)
b 0.20
Pathologic stage ($T3a vs. #T2b)
c 0.24
TOP2A Preoperative PSA ($10 vs. ,10 ng/ml) 1.0
Gleason grade ($4+3 vs. #3+4)
b 0.12
Pathologic stage ($T3a vs. #T2b)
c 0.06
E2F1 Preoperative PSA ($10 vs. ,10 ng/ml) 0.73
Gleason grade ($4+3 vs. #3+4)
b 0.82
Pathologic stage ($T3a vs. #T2b)
c 0.39
aTwo-sided Fisher’s exact test.
bStratification based on limited representation of Gleason 6 and 4+4 cases.
cStratifies pathologic stage based on organ confinement.
doi:10.1371/journal.pone.0020293.t002
Table 3. Receiver-operating characteristic (ROC) curve
analysis.
Variable Area under the curve
a
Preoperative PSA (per ng/ml)
b 0.658
Gleason grade ($4+3 vs. #3+4)
c 0.622
Pathologic stage ($T3a vs. #T2b)
d 0.690
Ki-67 0.572
TOPO2A 0.601
E2F1 0.599
Tri-marker proliferation index 0.642
Clinical model (PSA+grade+stage) 0.786
Clinical plus tri-marker proliferation index 0.816
aEvaluated at 8 years follow-up (the median follow-up time).
bAnalyzed as a continuous variable.
cStratification based on limited representation of Gleason 6 and 4+4 cases.
dStratifies pathologic stage based on organ confinement.
doi:10.1371/journal.pone.0020293.t003
Figure 2. Immunostaining of Ki-67, TOP2A and E2F1 are prognostic. (A) Immunostaining of proliferation markers Ki-67, TOP2A and E2F1;
representative positive and negative cases shown. (B) Pairwise comparison of immunostain scores across cases. Pearson correlation (R) values shown.
(C) Kaplan-Meier analysis of Ki-67 (,5% vs. $5% tumor nuclei), TOP2A (,5% vs. $5% tumor nuclei) and E2F1 (,50% vs. $50% tumor nuclei)
immunostaining. P-values (log-rank test) shown. (D) Kaplan-Meier analysis of combined marker staining (see keys). P-values (log-rank test) shown.
doi:10.1371/journal.pone.0020293.g002
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contained prostate cancer cases from radical prostatectomy
(Table 1), associated with a median clinical follow-up of eight
years. All three proliferation markers exhibited the expected
nuclear staining (Fig. 2A). Interestingly, while Ki-67 and TOP2A
typically stained only a small fraction of tumor nuclei, E2F1 often
stained the majority of tumor cells (Fig. 2A). Ki-67 and TOP2A
immunostaining across cases was significantly correlated (R=0.38,
P,0.001) (Fig. 2B). Ki-67 and E2F1 were less correlated (just
missing statistical significance) (R=0.13, P=0.06), and somewhat
surprisingly, TOP2A and E2F1 did not appear correlated
(R=0.00, P=0.50) (Fig. 2B).
To evaluate and compare prognostic value, we performed
Kaplan-Meier analyses on the set of 139 cases that were evaluable
for all three proliferation markers. Ki-67 positivity ($5% nuclei
staining) showed a strong trend towards earlier biochemical-
recurrence following prostatectomy (P=0.107) (Fig. 2C) (analysis
of the full set of 156 cases evaluable for Ki-67 reached statistical
significance; data not shown). TOP2A positivity ($5% nuclei
staining) and E2F1 positivity ($50% nuclei staining) were
significantly associated with earlier recurrence (P=0.028 and
P=0.043, respectively) (Fig. 2C). None of the three proliferation
biomarkers was significantly associated with other clinicopatho-
logic features, including preoperative PSA, Gleason grade and
pathologic stage (Table 2).
We also determined whether combining markers might enhance
prognostic value. A comparison of cases having no, one, two or
three positive proliferation markers showed significant differences
(P=0.009), in general with incremental numbers of positive
markers associated with earlier recurrence (Fig. 2D). Stratifying
cases with no or one positive marker, vs. cases with two or three
positive markers, hereafter termed the tri-marker ‘‘proliferation
index’’, provided the greatest prognostic significance (P=0.001),
with a hazard ratio of 2.6 (95% confidence interval 1.4–4.9). This
result was also evident by analysis of ROC curves (Table 3; note
the greater area under the curve for the tri-marker proliferation
index).
Notably, in a multivariate analysis that included known
prognostic markers – preoperative serum PSA, Gleason grade
and pathologic stage, – the composite proliferation index
remained a significant predictor (P=0.005) (Table 4). The
improved prognostication afforded by incorporating the prolifer-
ation index (compared to the clinicopathologic data alone) was
confirmed by comparison of Kaplan-Meier plots (Fig. 3A; note the
more significant log-rank test P-value) and of ROC curves (Table 3
and Fig. 3B; note the greater area under the curve).
Discussion
In this study, we assessed for prostate cancer the prognostic
utility of tissue biomarkers of cell proliferation, identified from
expression profiling patterns. Two biomarkers, TOP2A and E2F1,
scored by immunohistochemistry, were each prognostic (and the
classic marker Ki-67 nearly so). Notably, combining markers
further improved prognostic value. A composite proliferation
index (0,1 vs. 2,3 positive markers) provided the greatest prognostic
significance, and retained value when combined with currently
used prognostic factors.
The markers we evaluated were selected from among the
prostate cancer proliferation cluster genes. The ‘‘proliferation
signature’’ (reviewed in ref. [23]) is a commonly encountered
pattern in microarray studies. First reported in breast cancer cell
lines and tumors [24], the proliferation signature is prominent
across diverse cancer types (in comparison to normal tissue) [25].
Its membership significantly overlaps with cell-cycle regulated
genes [26], and its presence correlates with cell doubling times in
culture [27], and Ki-67 staining in tumors [24,25]. The
proliferation signature has also been found prognostic in breast
cancer [28,29] and in mantle cell lymphoma [30].
Gene signatures likely capture more information than assaying
individual genes, and indeed multi-gene signature assays have
reached clinical use [31–33]. Notably, two such breast cancer
prognostic/predictive signatures include genes reporting on cell
proliferation [31,32]. However, microarray testing is not easily
implemented in the clinical lab. We therefore asked whether a
small number of genes might effectively capture the relevant
information in the proliferation signature, by straight-forward
immunohistochemistry.
We evaluated three proliferation genes. Ki-67 (proliferation-
associated Ki-67 antigen), encoded by the MKI67 gene and
commonly identified by the MIB-1 antibody, is a nuclear antigen
expressed in proliferating but not quiescent cells [34], though its
specific function remains uncertain. Prior studies have shown Ki-
67 to be an independent predictor of outcome in prostate cancer
Table 4. Analysis of PSA recurrence-free survival.
Univariate analysis Hazard ratio (95% CI) P-value
a
Preoperative PSA (per ng/ml)
b 1.04 (1.02–1.06) ,0.001
Gleason grade ($4+3 vs. #3+4)
c 3.37 (1.74–6.53) ,0.001
Pathologic stage ($T3a vs. #T2b)
d 4.56 (2.24–9.32) ,0.001
Tri-marker proliferation index 2.64 (1.43–4.87) 0.001
Multivariate analysis
Preoperative PSA (per ng/ml) 1.04 (1.02–1.06) ,0.001
Gleason grade ($4+3 vs. #3+4) 2.66 (1.36–5.20) 0.004
Pathologic stage ($T3a vs. #T2b) 3.45 (1.68–7.10) ,0.001
Tri-marker proliferation index 2.47 (1.31–4.64) 0.005
aLog rank test (univariate analysis) or Wald test (multivariate analysis).
bAnalyzed as a continuous variable.
cStratification based on limited representation of Gleason 6 and 4+4 cases.
dStratifies pathologic stage based on organ confinement.
doi:10.1371/journal.pone.0020293.t004
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[40]. Consistent with these studies, we also found Ki-67 to be
prognostic, though it missed significance for the subset of cases
evaluable for all three proliferation markers.
TOP2A is a type II DNA topoisomerase, controlling the
topological state of DNA (by catalyzing transient double stranded
breaks) during DNA transcription, recombination, replication, and
chromosome partitioning at cell division [41]. TOP2A is also a
target of several anti-neoplastic drugs, e.g. doxorubicin and
etoposide. TOP2A expression by immunohistochemistry has been
shown to be prognostic in breast [42] and ovarian [43] cancers.
More recently, TOP2A transcript [44] and protein [45] levels
have been associated with systemic progression of prostate cancer.
Our own data corroborate this association.
E2F1 is a key transcriptional regulator of DNA replication and
cell-cycle progression, and is negatively regulated by the RB1
tumor suppressor [46]. The Rb/E2F pathway is disrupted in
most cancers [47]. Notably, a significant enrichment of E2F1
binding sites has been found among the promoter regions of
proliferation signature genes [48], and known targets include for
example CCNE1, CDC25A, MCM4, TK1, and CENPE [49].
Therefore, E2F1 is not only a proliferation signature gene, but
itself a transcriptional regulator of other proliferation signature
genes.
Figure 3. Incorporation of proliferation index improves prognostic value. (A) Kaplan-Meier analysis comparing multivariate models based
on clinicopathologic data (left) and clinicopathologic data plus the tri-marker proliferation index (right). Cases are grouped by tertile. Log-rank test P-
values are indicated. (B) ROC curve analysis comparing multivariate models based on clinicopathologic data (left) and clinicopathologic data plus the
tri-marker proliferation index (right). Analysis done at 8 years follow-up (the median follow-up time for the cohort). Areas under the curve (AUC) are
indicated.
doi:10.1371/journal.pone.0020293.g003
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[50] and lung [51] cancers, and we now extend this to prostate
cancer. Notably, while E2F1, Ki-67 and TOP2A transcript levels
are all cell-cycle regulated [26], we generally observed E2F1
immunostaining in a larger proportion of tumor cells, in contrast
to Ki-67 and TOP2A, which stained only a minority fraction of
cells. As such, scoring E2F1 positivity might be more straightfor-
ward and reproducible, and further evaluation of E2F1 as a
proliferation and prognostic marker in prostate and other cancer
types is warranted.
Importantly, we found that scoring three proliferation markers
provides superior prognostic information than scoring any single
one. Why should this be so? At the transcript level, E2F1, TOP2A
and Ki-67 peak at different stages of the cell cycle, G1/S, G2 and
G2/M, respectively [26]. It is therefore possible that the three
markers together provide a more complete snapshot of prolifer-
ating cells. Alternatively, using three markers might ‘‘smooth out’’
imprecision in pathologist scoring. Whether including more than
three proliferation markers might further improve performance is
unknown, though we note that three markers is within the range of
what is practical for histology labs (where antibody panels are
routinely ordered), and easier, quicker and cheaper than a
microarray.
In summary, we have shown that a tri-marker proliferation
index provides improved prognostic performance in prostate
cancer, adding value above currently used prognostic factors.
While validation in additional cohorts, and on whole tissue
sections, is warranted, our findings suggest that the proliferation
index might assist in risk stratification, for selecting appropriately
aggressive therapies (e.g. use of adjuvant therapy) and ultimately
improving patient outcomes. Cleary, clinical trials would be
required to assess the benefit with regard to prostate cancer-
associated morbidity and mortality. Finally, it is worth noting that
many anti-neoplastic drugs target cell proliferation [23], including
taxanes which show promise in the adjuvant/neoadjuvant setting
[4]. Therefore, it is possible (and worth investigating further) that
the proliferation index might also show utility in predicting
response to specific chemotherapy.
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